A.R.T. Advisors’s Regenxbio RGNX Stock Holding History

A.R.T. Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-45,011	Closed	-$1.89M	–	1557
2018 Q4	$1.89M	Buy	+45,011	New	+$2.64M	0.12%	248
2018 Q3	–	Sell	-10,064	Closed	-$722K	–	1649
2018 Q2	$722K	Sell	10,064 -50,495	-83%	-$2.41M	0.03%	778
2018 Q1	$1.81M	Buy	+60,559	New	+$1.76M	0.07%	427
2016 Q3	–	Sell	-27,600	Closed	-$220K	–	1074
2016 Q2	$220K	Buy	+27,600	New	+$306K	0.01%	1074

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

A.R.T. Advisors's RGNX Position: Q1 2019 in Review

A.R.T. Advisors sold out of Regenxbio (RGNX) in Q1 2019, closing a stake of 45,011 shares — an estimated $1.89M sold.

A.R.T. Advisors first reported a position in RGNX in Q2 2016 and held it in 4 quarters. The position peaked at $1.89M in Q4 2018. 211 funds tracked by Wall St. Rank hold RGNX as of Q1 2019.

A.R.T. Advisors reported no remaining Regenxbio position as of Q1 2019 after selling out during the quarter.
A.R.T. Advisors sold 45,011 Regenxbio shares in Q1 2019, an estimated $1.89M.
A.R.T. Advisors first reported a position in Regenxbio in Q2 2016 and held it in 4 quarters.
A.R.T. Advisors's Regenxbio position peaked at $1.89M in Q4 2018.
211 funds tracked by Wall St. Rank held Regenxbio as of Q1 2019.

Based on A.R.T. Advisors's 13F filing for Q1 2019, filed 15 May 2019.